CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞、NK 细胞，然后是巨噬细胞：人多能干细胞适应性免疫治疗的最新进展与挑战
英文原题：T, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells.
查看英文原题
T, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
适应性细胞免疫治疗，尤其是CAR-T（CAR-T）细胞疗法，推动了血液系统恶性肿瘤治疗的发展。然而，细胞来源依赖患者自身仍是一项重大限制。利用人多能干细胞分化为T细胞、NK细胞和巨噬细胞等免疫细胞，再通过CAR赋予其更强的肿瘤杀伤能力，已受到广泛关注。该策略有望解决患者可获得的免疫细胞数量不足、等待时间长以及伦理问题（将体细胞重编程为诱导多能干细胞（iPS细胞），可避免胚胎干细胞特有的伦理问题（Lo和Parham，2009））。不过，仍有若干重大挑战需要解决。本综述总结了基于人多能干细胞的免疫疗法研究进展、面临的挑战和未来方向。
展开英文摘要原文
Adaptive cellular immunotherapy, especially chimeric antigen receptor-T (CAR-T) cell therapy, has advanced the treatment of hematological malignancy.
However, major limitations still remain in the source of cells comes from the patients themselves. The use of human pluripotent stem cells to differentiate into immune cells, such as T cells, NK cells, and macrophages, then arm with chimeric antigen receptor (CAR) to enhance tumor killing has gained major attention.
It is expected to solve the low number of immune cells recovery from patients, long waiting periods, and ethical issues(reprogramming somatic cells to produce induced pluripotent stem cells (iPS cells) avoids the ethical issues unique to embryonic stem cells (Lo and Parham, 2009).
However, there are still major challenges to be further solved. This review summarizes the progress, challenges, and future direction in human pluripotent stem cell-based immunotherapy.
论文信息
- 作者
- Hang S、Wang N、Sugimura R
- 第一作者单位
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.Hong Kong
- 通讯作者单位
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong; Centre for Translational Stem Cell Biology, Hong Kong. Electronic address: rios@hku.hk.Hong Kong
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Differentiation; research in biological diversity2023 Mar-Apr
- 原文标识
- PubMed 36682340 · DOI 10.1016/j.diff.2023.01.001